Open Access
Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis
Xin Chang
1
,
Lei Xing
1, 2, 3, 4
,
Yi Wang
1
,
Chen Xi Yang
1
,
Yujing He
1
,
Tian-Jiao Zhou
1
,
Xiang-Dong Gao
2
,
Ling Li
5
,
Haiping Hao
6
,
Hu-Lin Jiang
1, 2, 3, 4
3
5
Publication type: Journal Article
Publication date: 2020-05-29
scimago Q1
wos Q1
SJR: 4.324
CiteScore: 19.6
Impact factor: 12.5
ISSN: 23752548
PubMed ID:
32518825
Multidisciplinary
Abstract
Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and fatal disease. However, IPF treatment has been limited by the low drug delivery efficiency to lungs and dysfunctional "injured" type II alveolar epithelial cell (AEC II). Here, we present surface-engineered nanoparticles (PER NPs) loading astaxanthin (AST) and trametinib (TRA) adhered to monocyte-derived multipotent cell (MOMC) forming programmed therapeutics (MOMC/PER). Specifically, the cell surface is designed to backpack plenty of PER NPs that reach directly to the lungs due to the homing characteristic of the MOMC and released PER NPs retarget injured AEC II after responding to the matrix metalloproteinase-2 (MMP-2) in IPF tissues. Then, released AST can enhance synergetic effect of TRA for inhibiting myofibroblast activation, and MOMC can also repair injured AEC II to promote damaged lung regeneration. Our findings provide proof of concept for developing a strategy for cell-mediated lung-targeted delivery platform carrying dual combined therapies to reverse IPF.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
9
|
|
|
Journal of Controlled Release
9 publications, 12%
|
|
|
Biomaterials
4 publications, 5.33%
|
|
|
Advanced Materials
4 publications, 5.33%
|
|
|
ACS Nano
3 publications, 4%
|
|
|
Science advances
3 publications, 4%
|
|
|
Advanced Drug Delivery Reviews
3 publications, 4%
|
|
|
Critical Reviews in Food Science and Nutrition
2 publications, 2.67%
|
|
|
Acta Pharmaceutica Sinica B
2 publications, 2.67%
|
|
|
Colloids and Surfaces B: Biointerfaces
1 publication, 1.33%
|
|
|
Nature Communications
1 publication, 1.33%
|
|
|
Polymers
1 publication, 1.33%
|
|
|
Frontiers in Pharmacology
1 publication, 1.33%
|
|
|
AAPS PharmSciTech
1 publication, 1.33%
|
|
|
Engineered Regeneration
1 publication, 1.33%
|
|
|
Small
1 publication, 1.33%
|
|
|
Materials Today Bio
1 publication, 1.33%
|
|
|
Matter
1 publication, 1.33%
|
|
|
European Journal of Pharmaceutics and Biopharmaceutics
1 publication, 1.33%
|
|
|
Advanced NanoBiomed Research
1 publication, 1.33%
|
|
|
Molecular Pharmaceutics
1 publication, 1.33%
|
|
|
Exploration
1 publication, 1.33%
|
|
|
Pharmacological Reports
1 publication, 1.33%
|
|
|
Interdisciplinary Biotechnological Advances
1 publication, 1.33%
|
|
|
Acta Biomaterialia
1 publication, 1.33%
|
|
|
Molecular Therapy - Nucleic Acids
1 publication, 1.33%
|
|
|
Chinese Chemical Letters
1 publication, 1.33%
|
|
|
Advanced Functional Materials
1 publication, 1.33%
|
|
|
Drug Delivery and Translational Research
1 publication, 1.33%
|
|
|
Phytomedicine
1 publication, 1.33%
|
|
|
1
2
3
4
5
6
7
8
9
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
34 publications, 45.33%
|
|
|
Wiley
12 publications, 16%
|
|
|
Springer Nature
9 publications, 12%
|
|
|
American Chemical Society (ACS)
4 publications, 5.33%
|
|
|
Taylor & Francis
3 publications, 4%
|
|
|
MDPI
3 publications, 4%
|
|
|
American Association for the Advancement of Science (AAAS)
3 publications, 4%
|
|
|
Frontiers Media S.A.
2 publications, 2.67%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 2.67%
|
|
|
Hindawi Limited
1 publication, 1.33%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
75
Total citations:
75
Citations from 2025:
18
(24%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Chang X. et al. Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis // Science advances. 2020. Vol. 6. No. 22.
GOST all authors (up to 50)
Copy
Chang X., Xing L., Wang Y., Yang C. X., He Y., Zhou T., Gao X., Li L., Hao H., Jiang H. Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis // Science advances. 2020. Vol. 6. No. 22.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1126/sciadv.aba3167
UR - https://doi.org/10.1126/sciadv.aba3167
TI - Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis
T2 - Science advances
AU - Chang, Xin
AU - Xing, Lei
AU - Wang, Yi
AU - Yang, Chen Xi
AU - He, Yujing
AU - Zhou, Tian-Jiao
AU - Gao, Xiang-Dong
AU - Li, Ling
AU - Hao, Haiping
AU - Jiang, Hu-Lin
PY - 2020
DA - 2020/05/29
PB - American Association for the Advancement of Science (AAAS)
IS - 22
VL - 6
PMID - 32518825
SN - 2375-2548
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Chang,
author = {Xin Chang and Lei Xing and Yi Wang and Chen Xi Yang and Yujing He and Tian-Jiao Zhou and Xiang-Dong Gao and Ling Li and Haiping Hao and Hu-Lin Jiang},
title = {Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis},
journal = {Science advances},
year = {2020},
volume = {6},
publisher = {American Association for the Advancement of Science (AAAS)},
month = {may},
url = {https://doi.org/10.1126/sciadv.aba3167},
number = {22},
doi = {10.1126/sciadv.aba3167}
}